| Document |
Document Title |
|
WO/2021/071033A1 |
The present invention relates to a method for preparing diethylamino hydroxybenzoyl hexyl benzoate and, specifically, to: a method for preparing diethylamino hydroxybenzoyl hexyl benzoate, which has a simple preparation process and can b...
|
|
WO/2021/066639A1 |
The present invention provides a tryptophan derivative used in agrochemistry, which has a preventive and corrective antiviral effect against begomovirus in plants, does not display phytotoxicity in field concentrations and is not toxic t...
|
|
WO/2021/067301A1 |
A compound that includes a menthol glycinate. The menthol glycinate includes a menthol connected to a glycine or glycine derivative, via an ester linkage. The groups on the N atom are referred to as R1 and R2, and R1 and R2 are independe...
|
|
WO/2021/052942A1 |
The present invention relates to a process for the solidification of hexyl 2-[4-(diethylamino)-2- hydroxybenzoyl]benzoate (INCI diethylamino hydroxybenzoyl hexyl benzoate, DHHB), wherein the process comprises a step (a) of applying a she...
|
|
WO/2021/055835A1 |
The application relates to lipids of the general Formula (A) wherein at least one of the two side chains contains a carbonate functional group (M and/or M' is -0C(=0)0-) and to empty or loaded lipid nanoparticles (LNPs) including such li...
|
|
WO/2021/052271A1 |
A magnolol derivative and a preparation method therefor and an application thereof. The magnolol derivative has a structure represented by formula (1). The magnolol derivative has good water solubility, is colorless and transparent after...
|
|
WO/2021/052269A1 |
Disclosed is a water-soluble composition, a preparation method, and an application thereof. The water-soluble composition is composed of a compound having a structure represented by formula (1) and a compound having a structure represent...
|
|
WO/2021/054421A1 |
Provided are: a crystal of a 1,3,5-triazine derivative or a solvate thereof; and a method for producing the same. The present invention pertains to a crystal of a compound represented by formula (I) or a solvate thereof, and a pharmace...
|
|
WO/2021/052270A1 |
The present invention relates to the field of honokiol derivatives. Disclosed are a honokiol derivative, a preparation method therefor and the use thereof, wherein the derivative has a structure as shown in formula (I). The honokiol deri...
|
|
WO/2021/055833A1 |
The application relates to lipids of Formula (A), Formula (B) and Formula (1-1), and to lipid nanoparticles (empty or loaded LNPs) including such a lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipi...
|
|
WO/2021/049876A1 |
Provided is a method for producing L-homoserine, comprising a step of contacting an L-homoserine derivative with a solid acid catalyst.
|
|
WO/2021/043117A1 |
Provided is a content, related substance and chiral isomer detection method for 2-((1S,2S,3R,6S,8S)-2-(aminomethyl)tricyclo[4.2.1.03,8]nonan
e-2-yl)acetate benzenesulfonate or a composition thereof. The content and related substance I ar...
|
|
WO/2021/034742A1 |
Low primary amine (LPA) polyaspartic esters are provided which comprise a reaction product of an aliphatic diamine and an excess of a Michael addition receptor optionally, in the presence of a C1-C10 alcohol, wherein the low primary amin...
|
|
WO/2021/026647A1 |
Disclosed herein is a lipid having a net charge at physiological pH, and being covalently attached to a lipid moiety. The lipid moiety comprises a hydrocarbon structure having two or more linked hydrocarbon chains, optionally having cis ...
|
|
WO/2021/029914A1 |
The present invention relates to opiate derived compositions and their antagonists useful in therapeutic areas associated with opioid receptor modulation. A 3-hexadienoate modification of the opioids is formulated to improve opiates' eng...
|
|
WO/2020/188478A8 |
The invention relates to rigidified pentadentate chelating agents of Formulae (I) and (II), which are useful for the [Al18F]2+ labelling of biomolecules. The chelating agents of the invention are used to form coordination complexes with ...
|
|
WO/2021/024041A1 |
The disclosure features pharmaceutical compositions formed from prodrug dimers for the extended delivery of a drug and for the treatment of a disease or condition.
|
|
WO/2021/021634A1 |
Compositions for delivering nucleic acids to cells or tissue microenvironments are provided. In one embodiment, the compositions are lipid nanoparticle compositions formulated to have reduced splenic and hepatic clearance. It has been di...
|
|
WO/2021/017645A1 |
The present invention relates to the field of medicine synthesis, relates to a racemic preparation method for preparing a chiral β-amino acid and a derivative thereof, and particularly relates to a racemization method for a sitagliptin ...
|
|
WO/2021/002407A1 |
Provided is a novel production method by which a fluoroalkyl group-containing compound can be efficiently synthesized. This method is for producing a compound represented by general formula (3) (Rf represents a C1-30 alkyl group substi...
|
|
WO/2021/001044A1 |
Object of the present invention is an improved process for the preparation of key intermediates for the synthesis of Eltrombopag, passing through/using intermediate 5'-Chloro-2'-hydroxy[1,1'-biphenyl]-3-carboxylic acid alkaline metal sal...
|
|
WO/2020/257940A1 |
The present application provides furosemide analogues of the general formula Z having activity as anti-Aβ aggregation agents and/or as inhibitors of Aβ induced neuroinflammation. Formula Z These compounds are useful in preventing, dela...
|
|
WO/2020/264460A1 |
Compounds of formula I: or a pharmaceutically acceptable salt, hydrate, and/or solvate thereof, wherein: R1 is a pharmaceutically acceptable polymeric moiety comprising a pharmaceutically acceptable polymer chain such that the carbonyl g...
|
|
WO/2020/262455A1 |
The present invention provides a means for increasing the solubility of even a poorly soluble amino acid without changing to an expensive peptide and also without changing the pH, and is characterized in that at least two kinds of amino ...
|
|
WO/2020/262452A1 |
The present invention addresses the problem of providing a novel hydrogen storage material containing a metal organic structure capable of effectively storing hydrogen. Hydrogen can be effectively stored using a hydrogen storage materi...
|
|
WO/2020/262406A1 |
[Problem] To provide a method for heating anhydrous sodium silicate (cullet), a chelating agent, and water to obtain a sodium silicate aqueous solution and a method for producing a high-purity silica sol using the sodium silicate aqueous...
|
|
WO/2020/262451A1 |
The invention addresses the problem that metal-organic frameworks have conventionally only been produced with terephthalic acids having a limited range of substituents even though the amount and type of gas stored thereby can vary depend...
|
|
WO/2020/262258A1 |
A method for producing a peptide compound including a step that uses a condensed polycyclic aromatic hydrocarbon compound represented by formula (1), a reagent for forming a protecting group that includes the compound, and the compound. ...
|
|
WO/2020/252589A1 |
The present document describes compounds, or pharmaceutically acceptable salt thereof, of a core formula (I) where R1 features an amine group, particularly useful in the formulation of lipid particles including nucleic acid therapeutic a...
|
|
WO/2020/257716A1 |
Disclosed are cationic lipids which are compounds of Formula (A). Cationic lipids provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly ...
|
|
WO/2020/254337A1 |
The invention concerns new quaternary ammonium compounds with surfactant properties and improved biodegradability.
|
|
WO/2020/251368A1 |
The present invention describes liposome formulations comprising a phospholipid, cholesterol and a fatty acid compound or fatty acid containing compound. Also, various medical uses of the liposome formulation are described.
|
|
WO/2020/251812A1 |
Provided is a method of making ethylenediaminetetraacetic acid (EDTA) comprising the steps: (a) providing a reaction mixture (a) comprising ethylenediamine (EDA) and glycolonitrile (GN), wherein reaction mixture (a) comprises 0% to 0.1% ...
|
|
WO/2020/248042A1 |
A liquid composition for use as a consumable stimulant; it has a consumable liquid solvent comprising water; caffeine at a concentration of at least 0,04 g / mL once dissolved in the consumable liquid solvent; and a tyrosine-based compou...
|
|
WO/2020/252336A1 |
These compounds are amino acid transporter inhibitors. Amino acid transporter inhibitors are useful to treat a variety of diseases disorders, or conditions including cancer.
|
|
WO/2020/251613A1 |
There is disclosed a process for the production of dodecanedioic acid and 11- aminoundecanoic acid, comprising: (1) reacting castor oil with a primary or secondary amine to form a amide; (2) isomerizing the amide in the presence of a cat...
|
|
WO/2020/247853A1 |
This invention provides for synthesis of citrulline from a transition metal complex of ornithine using cyanate to derivatize the terminal amino group of ornithine. The invention also provides improved methods for purification of citrulli...
|
|
WO/2020/003147A3 |
A hydrophilic polymer comprising pendent groups of the formula I: Wherein: W is independently selected from –OH, -COOH, -SO3H, -OPO3H, -O-(C1-4alkyl), -O-(C1-4alkyl)OH, -O-(C1-4alkyl)R2, -O-(C2H5O)qR1 –(C=O)-O-C1-4alkyl and –O-(C=O...
|
|
WO/2020/232597A1 |
The present invention provides a diamine compound, a preparation method therefor, and a thermosetting resin composition. The diamine compound has a structure as represented by structural formula (I). The structure of the diamine compound...
|
|
WO/2020/233651A1 |
Provided are an siRNA which inhibits purine nucleoside phosphorylase (PNP) gene expression, a pharmaceutical composition containing the siRNA, and an siRNA conjugate, capable of effectively treating and/or preventing abnormal uric acid m...
|
|
WO/2020/232542A1 |
The present disclosure relates to carbon dots, uses thereof and methods of manufacture thereof. For example, such carbon dots can be used in the production of biofuels such as biodiesel. For example, these carbon dots can be used as cata...
|
|
WO/2020/232304A1 |
Provided are compositions and methods that comprise the use of abscisic acid and L-arginine to improve foraging activity relative to the pollination performance of bees, and a composition to administer to bees containing abscisic acid an...
|
|
WO/2020/232227A1 |
The present invention provides methods for treating cancer. The present disclosure provides methods of treating cancer by increasing the oxidative stress on the cancer cell. In particular, the present disclosure is directed to methods of...
|
|
WO/2020/220963A1 |
The present invention relates to the field of surfactants. Disclosed are a novel photodegradable amphiphilic molecule and synthesis method therefor. The synthesis of the photodegradable amphiphilic molecule has five steps of reactions: (...
|
|
WO/2020/219876A1 |
The disclosure provides ionizable amine lipids and salts thereof (e.g., pharmaceutically acceptable salts thereof) useful for the delivery of biologically active agents, for example delivering biologically active agents to cells to prepa...
|
|
WO/2020/215895A1 |
The present invention relates to the technical field of medicine, and relates to derivatives represented by formula 1 and formula 2 in which a carboxylic acid group is introduced into the structure of ginkgolide B by means of a hydroxyl ...
|
|
WO/2020/212901A1 |
Disclosed are compounds having the following formula (I): Formula (I) wherein R is an alkylene chain having between 8 and 20 carbon atoms, and A is one or more anions having a total charge of -2, or R is a quaternary amine having the fol...
|
|
WO/2020/212399A1 |
The present invention relates to a method for the preparation of the preparation of ethyl (2S, 3S)-3-aminobicyclo [2.2.2] octane-2 -carboxylate from the β-keto ester (II) via a chiral transfer hydrogenation reaction in the presence of a...
|
|
WO/2020/212585A1 |
This invention relates to a process for producing cyanoacetates using aspartic acid as a precursor.
|
|
WO/2020/210485A1 |
Disclosed are processes for preparing α-carboxamide pyrrolidine derivatives, in particular (2S,5R)-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-2-carbo
xamide, and intermediates for use in said processes along with processes for prepari...
|
